A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer
Anticancer Research · 2025
DOI: 10.21873/anticanres.17672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Ummuhan Demir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Medeniyet University, Istanbul, Turkiye ummuhan.d…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Pyrvinium Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Prostate cancer is common in elderly men. Single treatment options are inadequate for effective therapy. In this study, three small-molecule inhibitors targeting three different pathways related to stemness were combined to obtain an effective antiproliferative effect on prostate cancer cell lines. These small molecules and their corresponding target were: KJ-Pyr-9 as an inhibitor of MYC proto-oncogene bHLH transcription factor (MYC); pyrvinium pamoate as an inhibitor of WNT; and glasdegib as an inhibitor of Sonic Hedgehog (SHH), which induces stem cell properties of cells. MATERIALS AND METHODS: Firstly, the half-maximal inhibitory concentration (IC50) and IC25 doses of each drug against the PC-3 cell line and dose optimization for combination of all three drugs were determined. PNT1A cells were used as a healthy control. 3D culture and scratch assays were applied to test efficiency of combined drug treatment. RESULTS: According to 2D culture results, the combination was synergistic in PC-3 while its effect was minimal in PNT1A. The combined treatment diminished both viability and size of 3D spheroids of PC-3 and LNCaP cells. In addition, the combined treatment reduced the migratory potential of PC-3 and LNCaP cells. CONCLUSION: The combined treatment proposed in this study is novel and promising in overcoming drug resistance and side-effects of single agents and may herald a new era in the treatment paradigm for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Medeniyet University, Istanbul, Turkiye ummuhan.demir@medeniyet.edu.tr.
- Science and Advanced Technologies Research Center (BILTAM), Istanbul Medeniyet University, Istanbul, Turkiye.
- Department of Molecular Biology and Genetics, Institute of Graduate Programs, Istanbul Technical University, Istanbul, Turkiye.
- Department of Molecular Biology and Genetics, Institute of Graduate Programs, Gebze Technical University, Istanbul, Turkiye.
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Medeniyet University, Istanbul, Turkiye.
Zitieren
APA
Demir, U., Badoglu, H., Cetin, I. N., & Bener, M. Y. (2025). A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17672
Vancouver
Demir U, Badoglu H, Cetin IN, Bener MY. A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer. Anticancer Research. 2025. doi:10.21873/anticanres.17672
BibTeX
@article{Demir2025,
author = {Demir, Ummuhan and Badoglu, Hilal and Cetin, Irem Nur and Bener, Muhammed Yasar},
title = {A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17672}
}
EUVIMED